The value of conventional long-term, carcinogenicity or reproductive studies would in many instances appear to depend upon the “insurance” they are held to provide and upon “no effect” levels, rather than upon the production of adverse effects that can be extrapolated to man. The development of alternatives to such studies necessitates refinement of the latter and the investigation of specific components and mechanisms of toxicity.
WeissB., WoodR.W., and MerigenW.H. (1983). Toxicity evaluation needs the intact animal. In The Role of Animals in Biomedical Research (ed. SechzerJ.A.). Annals of the New York Academy of Sciences, 406, pp. 82–91.
2.
PalmerA.K. (1974). Problems associated with the screening of drugs for possible teratogenic activity. In Experimental Embryology and Teratology (ed. WoolamD.H.M., MorrisG.M.), pp. 16–68. London: Paul Elek.
3.
KonoR. (1971). Subacute myelo-optico-neuropathy, a new neurological disease prevailing in Japan.Japanese Journal of Medical Science and Biology24, 195–216.
4.
MeadeT.W. (1975). Subacute myelo-optic-neuropathy and clioquinol: an epidemiological case history for diagnosis.British Journal of Preventive and Social Medicine29, 157–169.
5.
InoueY.K., and NishibeY. (1982). SMON and MS.Lancet, II, 716.
6.
SchmidK. (1977). The pharmacokinetics of clioquinol in animals and man.Läkartidningen74, 3003–3017.
7.
ThomannP.E., KoellaW.P., KrinkeG., PetermannH., ZakF., & HessR. (1974). The assessment of peripheral neurotoxicity in dogs: comparative studies with acrylamide and clioquinol.Agents and Actions4, 47–53.
8.
WordenA.N., HeywoodR., PrenticeD.E., ChestermanH., SkerrettK., and ThomannP.E. (1978). Clioquinol toxicity in the dog.Toxicology9, 227–238.
9.
RosnerI. (1976). Experimental analgesic nephropathy.CRC Critical Reviews in Toxicology2, 331–352.
10.
ZbindenG. (1976). Progress in Toxicology: Special Topics 2;1, 117 pp. Berlin: Springer.
11.
HildyardN. (1981). Thalidomide and after. In Cover Up: the Facts they Don't Want You to Know, pp. 147–176. London: New English Library.
12.
Department of Health and Social Security (1982). Guidelines for the testing of chemicals for carcinogenicity.Report on Health and Social Subjects25, 30 pp. London: HMSO.
13.
BarnesJ.M., and DenzF.A. (1954). Experimental methods used in determining chronic toxicity: a critical review.Pharmacological Reviews6, 191–242.
14.
FrazerA.C., and SharratM. (1969). The value and limitations of animal studies in the prediction of effects in man. In The Use of Animals in Toxicology Studies, pp. 4–14. Proceedings of a symposium held on 22nd January, 1969. London: UFAW.
15.
DayanA.D. (1981). The relative worth of animal testing. In Risk-Benefit Analysis in Drug Research (ed. CavallaJ.F.), pp. 97–112. Lancaster: MTP Press.
16.
BerryC.L. (1983). Development, differentiation and degenerative disease.Journal of the Royal Society of Medicine76, 176–182.
17.
BrambellF.W.R. (1944). The reproduction of the wild rabbit.Proceedings of the Zoological Society of London114, 1–45.
18.
BrambellF.W.R. (1947). The occurrence of fibrin in the yolk-sac contents of embryos during and immediately after implantation.Journal of Experimental Biology23, 332–345.
19.
PalmerA.K. (1971). Sporadic malformations in laboratory animals and their influence on drug testing. In Drugs and Fetal Development (ed. KlingbergM.A., AbramoviciA., ChemkeJ.), pp. 45–60. New York: Plenum Press.
20.
PalmerA.K. (1974). Problems associated with the screening of drugs for possible teratogenic activity. In Experimental Embryology and Teratology (ed. WoollamD.H.M., MorrisG.M.), pp. 16–33. London: Paul Elek.
21.
PalmerA.K. (1969). The Relationship Between Screening Tests for Drug Safety and Other Teratological Investigations. In Proceedings of the Symposium on Teratology (ed. Italian Society of Experimental Teratology), pp. 55–72. Proceedings of a meeting held in Como, Italy, October 1967. Amsterdam: Excerpta Medica International Congress Series No. 173.
22.
HeinonenO.P., SloneD., and ShapiroS. (1977). Birth Defects and Drugs in Pregnancy, 516 pp. Littleton, Massachusetts: Publishing Sciences Group.
23.
BarlowS.M., and SullivanF.L. (1982). Reproductive Hazards of Industrial Chemicals, 610 pp. London: Academic Press.
24.
ShephardN.W., BennettP.N., and InmanW.H.W. (1983). Human studies. In Animals and Alternatives in Toxicity Testing (ed. BallsM., RiddellR.J., WordenA.N.), pp. 429–444. Proceedings of a meeting held at the Royal Society of London, 1–3 November, 1982. London: Academic Press.
25.
HeywoodR. (1981). Target organ toxicity.Toxicology Letters8, 349–358.
26.
Committee on Safety of Medicines (1972). Carcinogenicity Tests of Oral Contraceptives, 30 pp. London: HMSO.
PerryW.L.M. (1950). Report on biological standards. VI. The design of toxicity tests. In Medical Research Council Special Report Series No. 270, 51 pp. London: HMSO.
